Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jason Chandler (NPI 1295778330)

Field	Value
Entity Type	Individual
Organization	Jason Chandler
Address	7945 Wolf River Boulevard
City	Germantown
State	TN
ZIP	38138
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 14, 2006

Payer Source	Total Paid
Medicare	$3.8M
Medicaid	$0

Key Findings

This provider is primarily an oncology infusion and management practice: the top billed items are high-cost oncology injectables such as J9271 (pembrolizumab) with $1.4M revenue (40.8% of this provider's total Medicare revenue), J9299 (nivolumab) with $557.3K revenue (15.8%), and J9144 (daratumumab) with $294.1K revenue (8.3%), and the mix also includes supportive agents and growth factors. The code mix (multiple monoclonal antibody/immunotherapy J-codes plus pegfilgrastim and denosumab) and the presence of infusion-associated chemotherapy administration codes indicate on-site infusion services and integrated clinical management rather than a purely consultative practice.

Revenue is highly concentrated in a small set of therapies: precomputed data show the top 3 Medicare codes by revenue account for 64.9% of this provider's total Medicare revenue, which signals dependence on a few high-cost drugs (notably pembrolizumab) for the majority of Medicare billings. That concentration creates sensitivity to utilization and reimbursement changes for those specific agents.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $3.8M while there is no Medicaid billing on file, so the practice operates without recorded Medicaid volume and is heavily reliant on Medicare patient revenue. Analysts should treat this provider as a Medicare-centric operation when assessing market exposure and payer negotiations.

Competitive standing on key products varies: the provider ranks #72 of 1841 nationally for J9271 (96th percentile) and is described as notably above typical national volume for that code, indicating a leading national presence for pembrolizumab administration. By contrast, J9299 and J9144 are ranked in mid-to-lower percentiles (75th and 46th respectively) and are described as typical or unremarkable volumes, so pembrolizumab drives the provider's above-average national footprint while other leading agents are more typical.

Outpatient E/M volume is unusually high relative to peers: 99214 shows 1.2K claims, $89 avg paid/claim, $104K revenue (3.0% of Medicare revenue) and ranks #7665 of 479517 providers nationally (98th percentile; extreme outlier). This combination of high E/M ranking with high infusion drug volume suggests extensive longitudinal management of Medicare patients in clinic rather than only episodic infusions.

On-site laboratory and monitoring activity supports an infusion-centered workflow: high-volume lab items such as 85025 (2.6K claims, $20.8K revenue) and 80048 (2.2K claims, $17.4K revenue) both rank in the 98th percentile nationally, and flow-cytometry add-on 88185 also appears on the top list. These lab testing patterns are consistent with frequent treatment monitoring and management of complex oncology patients receiving immunotherapy and chemotherapy.

Tenure is long enough to indicate an established practice: the NPI was enumerated on 2006-06-14 (~20 years ago), suggesting stable market presence and institutional experience in oncology care. That longevity combined with the Medicare revenue scale and code mix supports classifying the provider as an established medical oncology practice with a Medicare-heavy patient base.

There are some specialized or rare billing occurrences but generally typical volumes across many oncology drugs: a few codes (for example J9358) appear in small national provider pools and are reported as typical, unremarkable volume, while many other oncology and supportive-care codes fall in mid-percentiles. Overall, aside from the pembrolizumab and E/M extremes, the provider’s code-level footprint is consistent with a busy community medical oncology infusion practice rather than a broad multispecialty or hospital-based system.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

107 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	34,200	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	23,220	$20	$557.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	7,100	$20	$134.9K
J0897	Injection, denosumab, 1 mg	6,240	$20	$112.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,170	$90	$104K
J1930	Injection, lanreotide, 1 mg	2,280	$40	$98K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,690	$40	$94.2K
J9047	Injection, carfilzomib, 1 mg	2,370	$40	$85.3K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	500	$140	$71.5K

Showing 1–10 of 107

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 107 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Jason Chandler — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

107 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	50	17,400	$40	$776.1K
J9299	7	20	21,010	$20	$487.5K
J9144	16	20	10,080	$40	$466.3K
J1569	16	30	3,030	$40	$175.2K
J1930	4	10	2,880	$40	$162K
J9358	4	10	7,850	$20	$156.7K
J9047	5	10	3,090	$40	$117.8K
J2353	5	10	650	$150	$106.3K
J1449	5	10	3,630	$30	$98.6K
J1437	16	20	3,700	$20	$86.3K

Showing 1–10 of 107

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jason Chandler, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Shelby County Health Care Corporation	TN	General Acute Care Hospital	$0	$56.1M
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Jason Chandler, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Jason Chandler — Billing Profile & Reimbursement Data

Sign up for Jason Chandler — Billing Profile & Reimbursement Data policy alerts

Jason Chandler — Billing Profile & Reimbursement Data

Sign up for Jason Chandler — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References